Evidence map›Paper›PMID 38926677›Full record

ArticleBMC neuroscience2024

The angiotensin II receptors type 1 and 2 modulate astrocytes and their crosstalk with microglia and neurons in an in vitro model of ischemic stroke.

Daniel Navin Olschewski, Nilufar Nazarzadeh, Felix Lange, Anna Maria Koenig, Christina Kulka, Jella-Andrea Abraham, Stefan Johannes Blaschke, Rudolf Merkel, Bernd Hoffmann, Gereon Rudolf Fink and 3 more

Abstract read
In one paragraph

Article in BMC neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel Navin OlschewskiDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany. daniel.olschewski@uk-koeln.de.
Nilufar NazarzadehDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Felix LangeDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Anna Maria KoenigDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Christina KulkaDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Jella-Andrea AbrahamDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Stefan Johannes BlaschkeDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Rudolf MerkelDepartment of Mechanobiology, Institute of Biological Information Processing (IBI-2), Research Centre Juelich, Juelich, Germany.
Bernd HoffmannDepartment of Mechanobiology, Institute of Biological Information Processing (IBI-2), Research Centre Juelich, Juelich, Germany.
Gereon Rudolf FinkDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Michael SchroeterDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Maria Adele RuegerDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Sabine Ulrike VayDepartment of Neurology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Funding

Cologne Clinician Scientist Program 773/15-1Deutsche Forschungsgemeinschaft 431549029 - SFB 1451Gerok Program 3622/9900/11Köln Fortune Program 326/2020Köln Fortune Program 370/2019Marga und Walter Boll-Stiftung 210-10-15
6 · The paper itself

Abstract

backgroundAstrocytes are the most abundant cell type of the central nervous system and are fundamentally involved in homeostasis, neuroprotection, and synaptic plasticity. This regulatory function of astrocytes on their neighboring cells in the healthy brain is subject of current research. In the ischemic brain we assume disease specific differences in astrocytic acting. The renin-angiotensin-aldosterone system regulates arterial blood pressure through endothelial cells and perivascular musculature. Moreover, astrocytes express angiotensin II type 1 and 2 receptors. However, their role in astrocytic function has not yet been fully elucidated. We hypothesized that the angiotensin II receptors impact astrocyte function as revealed in an in vitro system mimicking cerebral ischemia. Astrocytes derived from neonatal wistar rats were exposed to telmisartan (angiotensin II type 1 receptor-blocker) or PD123319 (angiotensin II type 2 receptor-blocker) under normal conditions (control) or deprivation from oxygen and glucose. Conditioned medium (CM) of astrocytes was harvested to elucidate astrocyte-mediated indirect effects on microglia and cortical neurons.

resultThe blockade of angiotensin II type 1 receptor by telmisartan increased the survival of astrocytes during ischemic conditions in vitro without affecting their proliferation rate or disturbing their expression of S100A10, a marker of activation. The inhibition of the angiotensin II type 2 receptor pathway by PD123319 resulted in both increased expression of S100A10 and proliferation rate. The CM of telmisartan-treated astrocytes reduced the expression of pro-inflammatory mediators with simultaneous increase of anti-inflammatory markers in microglia. Increased neuronal activity was observed after treatment of neurons with CM of telmisartan- as well as PD123319-stimulated astrocytes.

conclusionData show that angiotensin II receptors have functional relevance for astrocytes that differs in healthy and ischemic conditions and effects surrounding microglia and neuronal activity via secretory signals. Above that, this work emphasizes the strong interference of the different cells in the CNS and that targeting astrocytes might serve as a therapeutic strategy to influence the acting of glia-neuronal network in de- and regenerative context.

Indexed as

Angiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersAstrocytesIschemic StrokeMicrogliaNeuronsRats, WistarReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2TelmisartanAnimalsAnimals, NewbornBenzimidazolesCell CommunicationCells, CulturedImidazolesAgtr2 protein, ratAngiotensin II Type 1 Receptor BlockersAngiotensin II Type 2 Receptor BlockersBenzimidazolesImidazolesPD 123319PyridinesReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2TelmisartanAstrocytesCerebral ischemiaCortical neuronal networkMEAMicroelectrode arrayMicrogliaNeuroinflammationPD123319Renin–angiotensin–aldosterone systemTelmisartan

Identifiers

PMID38926677
PMCPMC11202395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.